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hypertension, and insulin resistance, suggesting that systemic factors could
also play a role in the genesis of OA joint damage.
A number of deﬁned metabolic diseases may also lead to non-inﬂammatory
arthropathy with radiographic features predominantly of OA. The principal
conditions that predispose to secondary OA are ochronosis, wilson’s dis-
ease, acromegaly and hereditary hemochromatosis (HH). The most common
form of HH is an autosomal recessive iron overload disorder associated
with mutation of the HFE gene. Affected individuals may present with a
severe arthropathy mimicking OA, typically involving the second and third
metacarpophalangeal joints, which may seriously affect quality of life.
Other metabolic diseases, like chronic hypomagnesaemia or primary hyper-
parathyroidism may lead to deposition of calcium pyrophosphate crystals
within cartilage. These deposits, named chondrocalcinosis when identi-
ﬁed by X-Rays, are associated with OA, which may present with more
inﬂammatory symptoms, an atypical distribution and prominent cyst and
osteophyte formation on radiographs.
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Despite all the advances in bone and cartilage biology, particularly in
the recent bone and joint decade, there are still some deﬁciencies in our
understanding of the pathogenesis of osteoarthritis (OA), as well as our
ability to diagnose and treat OA. Nanomedicine is expected to improve
the ADL of patients with OA through the advances in the technology for
diagnosis and treatment.
(1) Oxidative DNA damage contributes to aging and degeneration of ar-
ticular cartilage. During the development of OA, mechanical and chemical
stresses on articular cartilage change the stable cellular activities of chon-
drocytes and produce excess amounts of reactive oxygen species (ROS) as
well as proinﬂammatory cytokines and chemokines. Studies have provided
ample conﬁrmation of the accumulation of ROS and the chondrocyte aging
in degenerated articular cartilage.
Our recent study revealed the potential involvement of accumulation of 8-
Oxoguanine, an oxidized form of guanine, and impairment of mitochondrial
DNA repair enzymes in the pathogenesis of OA. 8-Oxoguanine is produced
by ROS in large amounts in both DNA and nucleotide pools and is a major
causative lesion for mutagenesis by ROS in a variety of diseases.
We observed the increased level of 8-Oxoguanine and decreased level of
Ogg1 in osteoarthritic chondrocytes of degenerated cartilage in comparison
with chondrocytes of intact cartilage in animal models of OA and in patients
with OA, suggesting the involvement of the accumulation of 8-Oxoguanine
in articular chondrocytes and down-regulation of its repair enzyme Ogg1
in the degeneration of articular cartilage in OA. We found that over-
expression of mitochondria-targeted human hOgg1 in human osteoarthritis
chondrocytes prevents oxidant-induced mitochondrial dysfunction, OA re-
lating catabolic stress-induced caspase-9 activation and apoptosis in vitro.
Furthermore, hOgg1 silencing using siRNA reduced chondrocyte activity
and augments apoptosis in human ostearthritic chondrocytes.
(2) Application of nanotechnology to chondroprotection. In the previous
studies, we have focused on nanocarbon particle, fullerene (C60), which
acts a strong free radical scavenger, as an anti-oxidative agent, to prevent
the degeneration of articular cartilage in OA. We have demonstrated that
water-soluble fullerene has a potential as a protective agent against the
catabolic stress-induced degeneration of articular cartilage both in vitro
andin vivo OA models.
In this paper, we demonstrate that mitochondrial 8-Oxoguanine DNA
glycosylase regulates the cellular function and survival of osteoarthritic
chondrocytes in response to catabolic stresses in OA. In addition, we show
that C60 fullerene may inﬂuence the expressions of mitochondrial DNA
repair enzymes and their functions in osteoarthritic chondrocytes, suggest-
ing that C60 fullerene has a therapeutic potential, as a nanomedicine, to
protect against the degeneration of articular cartilage in OA. We would like
to conclude the pathomechanism of OA in terms of the chondrocyte ability
and function in response to oxidative stress by augmenting DNA repair.
(3) Application of bone and cartilage imaging. Magnetic resonance imag-
ing (MRI) is now thought an effective tool in the image diagnosis of OA.
However, spatial resolution of MRI is limited to a span of one to several
millimeters. While conventional X-ray imaging system has been used in
the image diagnosis of various diseases, cartilage cannot be depicted with
them. There has been a strong call for an X-ray imaging technology that can
depict cartilage. More recently, Kido K. et al. demonstrated a novel X-ray
imaging system which it would be easier to detect the onset of a disease,
to diagnose the stage of the disease, and to monitor the effect of treatment
for bone and cartilage diseases. We also show their excellent technology of
image diagnosis, an X-ray Talbot-Lau interferometry, for degenerated bone
and cartilage.
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F. Luyten
Univ. Hosp. KULeuven, Leuven, Belgium
Regenerative Medicine aims to reconstruct or regenerate damaged or lost
tissue function due to trauma, disease or congenital defects, ideally without
tissue scarring. As articular cartilage does not heal, restoring damaged joint
surfaces has been a typical example where regmed approaches have been
explored extensively for over 15 years.
With the adoption of a new regulatory framework for Advanced Therapy
Medicinal Products (ATMP) at the end of 2007, also for cellular and/or
combinations products, the path of product development has become more
clear. Characterization of the cellular product by viability, identity, potency
and purity together with appropriate preclinical and toxicity studies, and
validation of a good manufacturing process (GMP) are all part of and critical
in this track of development. So far, one autologous cartilage cell product
has obtained central regulatory approval for the repair of symptomatic
articular cartilage defects in the knee. The data of the short and long term
follow up conﬁrm structural superiority over microfracture, considered
the standard of care. Clinical superiority over microfracture is particularly
striking for patients with a relatively recent medical history (less then 5
years).
Additional explorative trials for cartilage repair using variations on autolo-
gous cell based approaches, including the use of collagen membranes, have
provided valuable information about study design, mechanisms of repair
and clinical outcome and have revealed that further improvements could
be achieved. Besides expanded autologous articular chondrocytes, the use
of allogenic progenitor cell populations are now considered as an important
goal.
Some promising results have been reported in animal studies using pro-
genitor and mesenchymal cell populations (MSC) in post-traumatic models
of osteoarthritis (OA). However, before being able to evaluate the role of
cellular therapies in OA, more detailed information is needed on many
aspects including mechanisms of action, the fate of the cells, choice of cell
type and tissue origin, and culture parameters. Indeed, the mechanisms by
which MSC may contribute to tissue repair in OA are diverse and include
trophic effects, anti-inﬂammatory effects and direct tissue repair through
engraftment. The use of biomarkers to identify mechanistic events and
patients responding to treatment is an important step forward for these
more sophisticated regenerative approaches in OA.
In conclusion, there is hope for regenerative medicine, in particular in joint
an skeletal applications.
I-20
IMPACT OF OSTEOARTHRITIS PAIN ON THE BRAIN
T.J. Schnitzer, A.V. Apkarian
Northwestern Univ. Feinberg Sch. of Med., Chicago, IL
Purpose: Chronic pain is a hallmark of osteoarthritis (OA), yet little is
known about its properties and representation in the brain. Previous
studies from our group in other pain states have demonstrated distinct
global and local brain morphological changes. The current investigations in
patients with OA were undertaken to compare this condition and ascertain
its speciﬁcity in comparison to other clinical chronic pain conditions.
Methods: Psychophysical measurements to examine the magnitude and
temporal properties of pain perception were coupled with fMRI to evaluate
brain activity in healthy controls and OA patients and relate brain activity to
clinical parameters of the disease. Voxel-based morphometry was utilized
to determine gray matter changes in OA and compared to other chronic
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pain states as well as healthy controls. Structural covariance analyses to
identify brain architectural (network) reorganization in OA patients was
also performed.
Results: In OA patients, stimulus-related brain activity could be distin-
guished from brain activity associated with spontaneous pain. The former
activated brain regions commonly observed for acute painful stimuli in
healthy subjects, while the latter engaged prefrontal-limbic regions that
closely correspond to areas observed activated in chronic neuropathic pain
conditions. In addition, arthritis-related and pain-related clinical character-
istics of knee OA also mapped to brain regions involved in the processing
of spontaneous pain and not acute pain. Morphologically, OA exhibited a
unique atrophy pattern compared to other chronic pain conditions, with a
speciﬁcity of 90%.
Conclusions: OA pain has a unique brain activation pattern, especially in
contrast to acute pain, and the regions involved have similarities with other
chronic pain conditions. Anatomically,OA imparts a speciﬁc reorganization
of the brain; this pattern is robust and may be able to be used as a
biomarker of OA in individual subjects.
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Mechanical factors play a signiﬁcant role in the development and pro-
gression of knee osteoarthritis (OA). Epidemiological studies have linked
abnormal limb alignment, obesity and joint instability to OA in humans.
Animal studies have shown mechanical disruptions to the joint can lead
to rapid cartilage degeneration. Ex vivo studies have established the sensi-
tivity of cartilage to abnormal loads. Recent studies describing the loss of
surface lubrication in the post-traumatic knee suggest that cartilage may
be at even higher risk from abnormal kinematics after knee injury. These
and other observations have led to the development of theoretical frame-
works that attempt to explain how altered joint mechanics may, alone
or in combination with biological/genetic factors, drive OA development.
These frameworks could provide a rational basis for assessing OA risk and
designing optimal interventions. However, there is sparse data to support
them, due primarily to two primary obstacles: the slow-developing nature
of OA in humans and the lack of tools for accurately assessing in vivo joint
mechanics.
There are no animal models that replicate human knee mechanics or
the slow time course of human OA development. Cross-sectional studies
cannot distinguish between altered mechanics that may have contributed
to OA development and those that were secondary to the disease process.
Cause-effect relationships can only be deﬁnitively established using serial
human studies with long follow-ups. Existing studies have suffered from
the lack of sensitive markers for early OA (or even a consensus as to how to
describe early-stage disease), and have typically incorporated only cursory
assessments of joint mechanics.
Frameworks for mechanically driven OA focus on the role of joint contact
kinematics (arthrokinematics), which have been traditionally diﬃcult to
assess. Arthrokinematics vary with loading and activity, and must be
assessed during dynamic, functional activities to provide relevant data.
Video-based kinematics studies are corrupted by motion of skin markers
relative to the underlying joint, and describe joint function only in terms of
rotations/translations about/along arbitrarily described axes. These data are
at best indirectly related to actual joint contact mechanics, and have been
of limited value for elucidating mechanical contributions to OA beyond
previously identiﬁed gross changes in joint mechanics (e.g. varus alignment
and increased external adduction knee moment).
New imaging technologies have emerged for assessing joint function.
Advanced MRI techniques enable direct determination of cartilage con-
tact for static or quasi-static joint positions. Dual ﬂuoroscopic imaging, com-
Figure 1. Estimated joint contact patterns after footstrike during running. ACL in-
jured/reconstructed knee on right, contralateral/uninjured knee on left.
bined with soft tissue structural information (from static MRI) can provide
high-accuracy estimates of cartilage surface interactions during relatively
slow activities. At the University of Pittsburgh, we are utilizing a custom-
designed Dynamic Stereo X-ray (DSX) system that employs high-power,
short-duration pulsed x-ray to achieve 0.1 to 0.3 mm accuracy at high
frame rates for a wide range of activities (from gait to running/jump
landings). Our previous DSX studies using an ACL-deﬁcient canine model
have identiﬁed speciﬁc arthrokinematic abnormalities, such as altered
dynamic contact locations and increased shear contact velocities, that are
predictive of rapid OA development. Human studies of patients at high
risk for OA (due to ligament and meniscal injuries) are revealing similar
alterations in arthrokinematics. Improvements in biological and imaging
markers for disease tracking are also providing new opportunities for
linking these mechanical alterations to OA over shorter timeframes. These
developments have led to long-term studies that are currently underway
to determine if there are speciﬁc arthrokinematic factors predictive of OA
development, and if treatments can be designed that will better restore
normal arthrokinematics and reduce OA incidence after knee injury.
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Purpose: Here we will review the links between degeneration of articular
cartilage and of the intervertebral disc; these cartilaginous tissues are
strongly associated with the painful and disabling disorders of osteoarthri-
tis and low-back pain respectively. Both tissues consist primarily of an
extracellular matrix composed mainly of ﬁbrillar collagens and aggrecan.
They are both avascular and hence can only sustain a small population of
the resident cells responsible for synthesizing and maintaining the matrix.
However there are also dissimilarities between disc and articular cartilage
for instance in regard to development, cell phenotypes and details of matrix
composition and organization as well as joint function.
In cartilage and disc degeneration, inﬂammatory cytokines and matrix
metalloproteases are upregulated; consequent matrix degradation results
in tissues unable to fulﬁll their primary biomechanical role with adverse
consequences for joint and spinal mechanics respectively. However al-
though the degradative processes appear similar, the initial pathways may
be very different; loss of nutrient supply for instance appears a major factor
for development of disc degeneration but not for osteoarthritis In addition,
although osteoarthritis and disc degeneration both appear to have a major
genetic component there is no strong evidence at present that those at risk
of developing osteoarthritis are also susceptible to disc related problems.
Conclusions: Examining similarities and differences between genetic and
other risk factors in relation to development and progression of os-
teoarthritis and disc-degeneration related problems could lead to better
understanding of both disorders.
